Seronegative Myasthenia Gravis

Some myasthenia gravis (MG) patients do not have detectable acetylcholine receptor (AChR) antibodies and have been termed “seronegative” (SNMG) in many previous studies. A high proportion of patients with purely ocular symptoms, ocular MG, are seronegative; this may be because the sensitivity of the assay is insufficient to detect low levels of circulating AChR antibodies and because of intrinsic differences in the ocular muscles that make them more susceptible to circulating factors. Seronegative generalized myasthenia is proving to be heterogeneous both clinically and immunologically. Plasma from SNMG patients often contains a factor, probably an immunoglobulin M antibody, that alters AChR function in in vitro assays, but its target is not yet clear. A variable proportion of SNMG patients have antibodies to the muscle-specific tyrosine kinase (MuSK). These antibodies are directed against the extracellular domain of MuSK and inhibit agrin-induced AChR clustering in muscle myotubes. Although the role of these antibodies in causing myasthenic symptoms in vivo has not been elucidated, MuSK antibodies appear to define a group of patients who are often female with bulbar weakness, contrasting with MuSK antibody-negative SNMG patients who are more likely to have generalized weakness. MuSK antibody-positive patients may also differ in the distribution of their electrophysiological abnormalities and their responses to treatments.

KEYWORDS

Myasthenia - seronegative - muscle-specific kinase - MuSK - acetylcholine receptor desensitization

REFERENCES

• 1 Lindstrom J M, Seybold M E, Lennon V A, Whittingham S, Duane D D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.  Neurology. 1976;  26 1054-1059
• 2 Lefvert A K, Bergstrom K. Acetylcholine receptor antibody in myasthenia gravis: purification and characterization.  Scand J Immunol. 1978;  8 525-533
• 3 Sanders D B, Andrews I, Howard J F, Massey J M. Seronegative myasthenia gravis.  Neurology. 1978;  28 266-272
• 4 Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.  J Neurol Neurosurg Psychiatry. 1985;  48 1246-1252
• 5 Somner N, Melms A, Weller M, Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.  Doc Ophthalmol. 1993;  84 309-333
• 6 Padua L, Stalberg E, LoMonaco M, Evoli A, Batocchi A, Tonali P. SFEMG in ocular myasthenia gravis.  Clin Neurophysiol. 2000;  111 1203-1207
• 7 Sadeh M, Stern L Z. Observations on the innervation of human extraocular muscles.  J Neurol Sci. 1984;  66 295-305
• 8 Kaminski H J, Richmonds C R, Kusner L L, Mitsumoto H. Differential susceptibility of the ocular motor system to disease.  Ann N Y Acad Sci. 2002;  956 42-54
• 9 Kaminski H J, Kusner L L, Block C H. Expression of acetylcholine receptor isoforms at extraocular muscle endplates.  Invest Ophthalmol Vis Sci. 1996;  37 345-351
• 10 Horton R M, Conti-Tronconi B M, Manfredi A A. ACh receptor in ocular MG.  Neurology. 1994;  44 778-779
• 11 MacLennan C, Beeson D, Buijs A M et al.. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis.  Ann Neurol. 1997;  41 423-431
• 12 Vincent A, Newland C, Brueton L et al.. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen.  Lancet. 1995;  346 24-25
• 13 Senanayake N, Roman G C. Disorders of neuromuscular transmission due to natural environmental toxins.  J Neurol Sci. 1992;  107 1-13
• 14 Fischer M D, Gorospe J R, Felder E et al.. Expression profiling reveals metabolic and structural components of extraocular muscles.  Physiol Genomics. 2002;  9 71-84
• 15 Khanna S, Richmonds C R, Kaminski H J, Porter J D. Molecular organization of the extraocular muscle neuromuscular junction: partial conservation of and divergence from the skeletal muscle prototype.  Invest Ophthalmol Vis Sci. 2003;  44 1918-1926
• 16 Nemoto Y, Kuwabara S, Kawaguchi N, Vincent A, Hattori T. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis.  Muscle Nerve. , Submitted for publication
• 17 Evoli A, Tonali P A, Padua L et al.. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.  Brain. 2003;  126 2304-2311
• 18 Vincent A, Li Z, Hart A et al.. Seronegative myasthenia gravis. Evidence for plasma factor(s) interfering with acetylcholine receptor function.  Ann N Y Acad Sci. 1993;  681 529-538
• 19 Drachman D B, de Silva S, Ramsay D, Pestronk A. Humoral pathogenesis of myasthenia gravis.  Ann N Y Acad Sci. 1987;  505 90-105
• 20 Tsujihata M, Yoshimura T, Satoh A et al.. Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis.  Neurology. 1989;  39 1359-1363
• 21 Verma P K, Oger J J. Seronegative generalized myasthenia gravis: low frequency of thymic pathology.  Neurology. 1992;  42 586-589
• 22 Willcox N, Schluep M, Ritter M A, Newsom-Davis J. The thymus in seronegative myasthenia gravis patients.  J Neurol. 1991;  238 256-261
• 23 Mier A K, Havard C W. Diaphragmatic myasthenia in mother and child.  Postgrad Med J. 1985;  61 725-727
• 24 Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity.  Lancet. 1986;  1 116-119
• 25 Evoli A, Batocchi A P, Lo Monaco M et al.. Clinical heterogeneity of seronegative myasthenia gravis.  Neuromuscul Disord. 1996;  6 155-161
• 26 Burges J, Vincent A, Molenaar P C et al.. Passive transfer of seronegative myasthenia gravis to mice.  Muscle Nerve. 1994;  17 1393-1400
• 27 Blaes F, Beeson D, Plested P et al.. IgG from “seronegative” myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor.  Ann Neurol. 2000;  47 504-510
• 28 Poea S, Guyon T, Bidault J et al.. Modulation of acetylcholine receptor expression in seronegative myasthenia gravis.  Ann Neurol. 2000;  48 696-705
• 29 Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction.  Muscle Nerve. 2002;  25 4-16
• 30 Hoch W, McConville J, Helms S et al.. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.  Nat Med. 2001;  7 365-368
• 31 Scuderi F, Marino M, Colonna L et al.. Anti-p110 autoantibodies identify a subtype of “seronegative” myasthenia gravis with prominent oculobulbar involvement.  Lab Invest. 2002;  82 1139-1146
• 32 McConville J, Farrugia M E, Beeson D et al.. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.  Ann Neurol. 2004;  55 580-584
• 33 Plested C P, Tang T, Spreadbury I et al.. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG.  Neurology. 2002;  59 1682-1688
• 34 Yamamoto T, Vincent A, Ciulla T A et al.. Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM.  Ann Neurol. 1991;  30 550-557
• 35 Spreadbury I, Kishore U, Beeson D, Vincent A. A non-IgG factor in seronegative myasthenia gravis causes inhibition of muscle acetylcholine receptors correlated with desensitisation. Submitted for publication
• 36 Sanders D B, El-Salem K, Massey J M et al.. Clinical aspects of MuSK antibody positive seronegative MG.  Neurology. 2003;  60 1978-1980
• 37 Newsom-Davis J, McConville J, Kennett R, Anslow P, Hoch W, Vincent A. Anti-MuSK antibodies in seronegative myasthenia gravis: a cause of denervation.  J Neurol Neurosurg Psychiatry. 2001;  71 421
• 38 Zhou S L, McConville J, Chaudhry V et al.. Clinical comparison of MuSK antibody positive and negative myasthenic patients.  Muscle Nerve. , In press
• 39 Burke G, Cossins J, Maxwell S et al.. Rapsyn mutations in hereditary myasthenia. Distinct early- and late- onset phenotypes.  Neurology. 2003;  61 826-828
• 40 Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets.  Lancet Neurol. 2003;  2 99-106